Viventia Biotech Inc. Report issue

For profit Phase 1 Phase 3
Founded: Winnipeg Canada (1995)
Status: Acquired by Sesen Bio (2016)

Organization Overview

First Clinical Trial
2005
NCT00412776
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novopharm Ltd | Viventia Bio

Active Ingredients

Drugs in Phase 3 Trials (1)

proxinium (4 trials)

Drugs in Phase 1 Trials (1)

vb6-845 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma in Situ (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Head and Neck Neoplasms (Phase 3)

Mouth Neoplasms (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Glandular and Epithelial (Phase 1)

Neoplasms, Squamous Cell (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2